dc.contributor.author | Cremolini, C | |
dc.contributor.author | Benelli, M | |
dc.contributor.author | Fontana, E | |
dc.contributor.author | Pagani, F | |
dc.contributor.author | Rossini, D | |
dc.contributor.author | Fucà, G | |
dc.contributor.author | Busico, A | |
dc.contributor.author | Conca, E | |
dc.contributor.author | Di Donato, S | |
dc.contributor.author | Loupakis, F | |
dc.contributor.author | Schirripa, M | |
dc.contributor.author | Lonardi, S | |
dc.contributor.author | Borelli, B | |
dc.contributor.author | Ongaro, E | |
dc.contributor.author | Eason, K | |
dc.contributor.author | Morano, F | |
dc.contributor.author | Casagrande, M | |
dc.contributor.author | Fassan, M | |
dc.contributor.author | Sadanandam, A | |
dc.contributor.author | de Braud, F | |
dc.contributor.author | Falcone, A | |
dc.contributor.author | Pietrantonio, F | |
dc.date.accessioned | 2019-04-23T11:50:42Z | |
dc.date.issued | 2019-03-01 | |
dc.identifier.citation | ESMO open, 2019, 4 (2), pp. e000489 - ? | |
dc.identifier.issn | 2059-7029 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3198 | |
dc.identifier.eissn | 2059-7029 | |
dc.identifier.doi | 10.1136/esmoopen-2019-000489 | |
dc.description.abstract | OBJECTIVE: Primary tumour location is regarded as a reliable surrogate of colorectal cancer biology. Sensitivity to anti-EGFRs (Epidermal Growth Factor Receptor) of metastatic transverse colon cancers (mTCCs) has usually been assumed similar to right-sided tumours; however, evidence about the clinical behaviour of mTCC is limited. Thus, to verify sensitivity of mTCC to anti-EGFRs we conducted the present study. METHODS: Patients with RAS/BRAF wild-type microsatellite stable (MSS) mTCC receiving anti-EGFR monotherapy, or in combination with irinotecan if clearly irinotecan-refractory, were included. Hypothesising an overall response rate (ORR) of 35%, 11 patients, of whom at least 3 were responders, were necessary to be able to reject the null hypothesis of an ORR of 5%, with α and β errors of 0.05 and 0.20. PRESSING panel and consensus molecular subtypes (CMS) were assessed on tumour samples, whereas in-silico data were obtained from TCGA dataset. RESULTS: Among nine eligible patients, four and three achieved response and disease stabilisation (ORR 44%). At a median follow-up of 23.1 months, median progression-free survival and overall survival were 7.3 (95% CI 3.9 to NA) and 15.0 months (95% CI 10.0 to NA), respectively. A MET amplification and an ERBB4 S303F substitution were detected in patients with rapid disease progression, while others had PRESSING panel-negative tumours with CMS2 or CMS4 subtypes. CONCLUSIONS: RAS/BRAF wild-type MSS mTCCs may be sensitive to anti-EGFRs, as confirmed by molecular analyses. | |
dc.format | Electronic-eCollection | |
dc.format.extent | e000489 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.title | Benefit from anti-EGFRs in RAS and BRAF wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2019-02-06 | |
rioxxterms.versionofrecord | 10.1136/esmoopen-2019-000489 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
rioxxterms.licenseref.startdate | 2019-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | ESMO open | |
pubs.issue | 2 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Systems and Precision Cancer Medicine | |
pubs.organisational-group | /ICR/Students | |
pubs.organisational-group | /ICR/Students/PhD and MPhil | |
pubs.organisational-group | /ICR/Students/PhD and MPhil/16/17 Starting Cohort | |
pubs.publication-status | Published | |
pubs.volume | 4 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Systems and Precision Cancer Medicine | |
dc.contributor.icrauthor | Fontana, Elisa | |
dc.contributor.icrauthor | Eason, Katherine | |